Compare ALAR & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALAR | MNOV |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.8M | 66.9M |
| IPO Year | 2018 | 2004 |
| Metric | ALAR | MNOV |
|---|---|---|
| Price | $6.23 | $1.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $14.00 | $7.50 |
| AVG Volume (30 Days) | 37.6K | ★ 50.6K |
| Earning Date | 03-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | $33.30 | N/A |
| Revenue Next Year | $30.53 | N/A |
| P/E Ratio | $44.31 | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $5.50 | $1.17 |
| 52 Week High | $18.00 | $1.96 |
| Indicator | ALAR | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 45.28 | 51.45 |
| Support Level | $5.50 | $1.40 |
| Resistance Level | $7.76 | $1.60 |
| Average True Range (ATR) | 0.42 | 0.06 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 59.02 | 43.52 |
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.